Edinburgh-based biotechnology firm, Calcivis, has secured £5m in funding to roll out its cutting-edge dental technology.

The firm's patented system enables early detection of tooth decay - which in turn can enable timely preventive treatment - by deploying a biologic diagnostic agent in combination with an imaging device. Calcivis aims to revolutionise early-intervention diagnostics in dentistry. Its innovative technology uses bioluminescence to highlight quickly and clearly where preventive measures are required before decay becomes irreversible.

Animal Health Angels has made its first investment is in Marleybones, a female founded business which is a fresh dog food brand known for its unique pantry fresh® solution.

This is part of a £900k seed funding led by JamJar Investments, the venture capital firm set up by the founders of innocent drinks, and further supported by Active Partners, the consumer investor behind Soho house, Rapha and KatKin. The funds will be used to grow the Marleybones team, expand its presence in both online and offline channels and broaden its retail footprint after its recent UK launches in Waitrose and Whole Foods Market.

Bridgend-based AI technology firm Clinithink is helping to improve patient care, relieve workloads for stretched clinicians and deliver significant savings to the NHS with investment from the Development Bank of Wales.

CryoLogyx, a University of Warwick spinout redefining cell technology through cryopreservation, has closed an oversubscribed seed funding round. The £500,000 investment came from private UK business angels and the Wider Oxford Technology Angel Network (WOTAN), which includes previous investors Oxford Technology Management. 

Newcastle University spinout Jetbio is introducing 3D bioprinting products in the global multi-billion-dollar 3D bioprinting market for drug discovery, tissue engineering and regenerative medicine.

Newcells Biotech, whose laboratory models are used in drug development and reduce reliance on animal testing, has raised a further £2.35m to boost its growth and help establish itself as a global leader in its field. 

The Newcastle-based company has secured funding from existing investors including the North East Venture Fund, supported by the European Regional Development Fund and managed by Mercia Ventures, Mercia’s own funds and Northstar Ventures. It brings the total raised by the company to date to over £12m.

ITALY: The Investors Club has invested in the 10 million euro round of Resalis Therapeutics.  The club gave a special thanks to its champion Guido Bonazzola, who contributed in a fundamental way to the realization of this initiative. Guido's active participation and commitment helped make this significant investment possible.

London startup, Koalaa, whose world-first soft prosthetic arms are aiding independence for individuals with limb differences around the world, has closed a funding round of $1.2 million led by British Design Fund.

MIP Discovery, an innovative developer of non-biological affinity reagents designed to accelerate the development and production of cell and gene therapies, has closed a £7m (~$9m USD) Series A financing round led by Mercia Ventures. Existing investor Calculus Capital also participated in the round, along with Angel investors.

Cambridge-based Infersens has launched Cortense®, its first commercially available solution to transform Legionella risk management and dramatically cut water waste.

London startup, Koalaa, whose world-first soft prosthetic arms are aiding independence for individuals with limb differences around the world, has closed a funding round of $1.2 million (£925,000).  The round was initiated by existing investor British Design Fund and includes £200,000 secured from the Imperial College Enterprise Fund II (ICEF), which invests in startup companies that have a strong connection to the University.  Business angels also took part in the round. The funds raised in this round, which started in July 2022, are being used to expand Koalaa’s business internationally.

PulmoBioMed  - a Northumbria University spin-out which has developed a new lung test that could lead to earlier diagnosis of asthma and other conditions - has raised £1.4m to help commercialise its technology and target the US market.  The investment round was led by the North East Venture Fund, supported by the European Regional Development Fund and managed by Mercia Ventures, and included Northumbria University, SFC Capital and private investors in the USA, EU and UK. The company has also secured a £700,000 grant from Innovate UK to help it demonstrate the benefits of its technology.